Table 1 10-year event-free survival and 10-year overall survival by treatment group
n ASCT/MT | 10-year event-free survival, % (95% CI) | P log rankb | 10-year overall survival, % (95% CI) | P log rankb | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
ASCT | MT | HR (95% CI) | P log ranka | ASCT | MT | HR (95% CI) | P log ranka | ||||
Intention to treat | |||||||||||
All | 149/146 | 36 (28–44) | 27 (19–35) | 1.39 (1.05–1.85) | 0.023 | 0.022 | 41 (33–49) | 35 (27–43) | 1.28 (0.95–1.73) | 0.100 | 0.075 |
CR/VGPRafter induction chemotherapy | 82/81 | 45 (33–57) | 30 (20–40) | 1.72 (1.15–2.58) | 0.008 | 0.008 | 49 (40–58) | 38 (28–48) | 1.52 (1.00–2.32) | 0.051 | 0.027 |
PR/MR/SD after induction chemotherapy | 48/52 | 36 (22–50) | 29 (17–41) | 1.36 (0.84–2.21) | 0.216 | 0.203 | 40 (26–54) | 35 (21–49) | 1.25 (0.75–2.08) | 0.386 | 0.456 |
Raised LDH at diagnosis | 131/131 | 34 (26–42) | 25 (17–33) | 1.35 (1.00–1.81) | 0.048 | 0.046 | 39 (31–47) | 31 (23–39) | 1.28 (0.94–1.74) | 0.112 | 0.088 |
Normal LDH at diagnosis | 15/14 | 60 (33–87) | 46 (19–73) | 1.87 (0.59–5.90) | 0.281 | 0.281 | 67 (40–94) | 62 (37–87) | 1.61 (0.43–6.02) | 0.474 | 0.474 |
MYCN amplificationa | 63/51 | 31 (19–43) | 20 (8–32) | 1.39 (0.89–2.15) | 0.144 | 0.144 | 34 (22–46) | 27 (15–39) | 1.28 (0.81–2.01) | 0.291 | 0.291 |
No MYCN amplification | 83/93 | 41 (29–53) | 30 (20–40) | 1.50 (1.02–2.19) | 0.037 | 0.037 | 47 (35–59) | 39 (29–49) | 1.39 (0.93–2.08) | 0.112 | 0.078 |
Stage 4 and age >1 year | 128/121 | 34 (26–42) | 26 (18–34) | 1.39 (1.03–1.88) | 0.033 | 0.032 | 38 (30–46) | 33 (25–41) | 1.25 (0.91–1.71) | 0.167 | 0.131 |
Stage 1, 2, 3 or 4S or stage 4 age <1 year | 21/25 | 53 (31–75) | 35 (15–55) | 1.52 (0.66–3.47) | 0.323 | 0.323 | 63 (41–85) | 43 (23–63) | 1.73 (0.69–4.36) | 0.237 | 0.237 |
ch14.18 treatment | 79/81 | 47 (35–59) | 34 (24–44) | 1.17 (0.50–2.74) | 0.017 | 0.022 | 49 (37–61) | 41 (29–53) | 1.46 (0.95–2.25) | 0.086 | 0.057 |
Isotretinoin treatment | 24/15 | 41 (21–61) | 36 (11–61) | 1.65 (1.09–2.51) | 0.718 | 0.619 | 50 (28–72) | 43 (18–68) | 1.16 (0.47–2.88) | 0.753 | 0.939 |
As treated | |||||||||||
All | 110/102 | 43 (32–54) | 26 (18–34) | 1.75 (1.24–2.47) | 0.001 | 0.001 | 46 (36–56) | 32 (22–42) | 1.54 (1.08–2.20) | 0.017 | 0.017 |
CR/VGPR after induction chemotherapy | 73/69 | 46 (34–58) | 30 (18–42) | 1.85 (1.19–2.87) | 0.005 | 0.010 | 51 (39–63) | 36 (24–48) | 1.65 (1.05–2.61) | 0.030 | 0.030 |
PR/MR/SD after induction chemotherapy | 37/32 | 38 (26–50) | 19 (5–33) | 1.49 (0.84–2.63) | 0.170 | 0.074 | 38 (22–54) | 23 (7–39) | 1.29 (0.72–2.31) | 0.385 | 0.385 |
Raised LDH at diagnosis | 97/94 | 39 (29–49) | 27 (17–37) | 1.58 (1.10–2.26) | 0.012 | 0.011 | 42 (32–52) | 31 (21–41) | 1.45 (1.01–2.10) | 0.045 | 0.046 |
Normal LDH at diagnosis | 11/7 | 81 (57–105) | N.A. | 7.59 (1.42–40.47) | 0.006 | 0.006 | 81 (57–105) | 33 (N.A.) | 4.21 (0.77–23.14) | 0.072 | 0.072 |
MYCN amplification | 48/39 | 33 (19–47) | 20 (6–34) | 1.81 (1.09–3.01) | 0.021 | 0.021 | 38 (24–52) | 20 (6–34) | 1.84 (1.09–3.08) | 0.020 | 0.020 |
No MYCN amplification | 60/57 | 52 (38–66) | 29 (17–41) | 1.97 (1.22–3.19) | 0.005 | 0.004 | 53 (39–67) | 38 (26–60) | 1.54 (0.93–2.54) | 0.092 | 0.082 |
Stage 4 and age >1 year | 95/87 | 42 (32–52) | 25 (15–35) | 1.67 (1.16–2.41) | 0.006 | 0.005 | 43 (33–53) | 31 (21–41) | 1.41 (0.97–2.06) | 0.070 | 0.069 |
Stage 1, 2, 3 or 4S or stage 4 age <1 year | 15/15 | 54 (27–81) | 36 (11–61) | 2.35 (0.83–6.66) | 0.098 | 0.098 | 69 (44–94) | 36 (11–61) | 3.02 (0.93–9.86) | 0.054 | 0.054 |
ch14.18 treatment | 75/71 | 48 (36–60) | 34 (22–46) | 1.51 (0.97–2.33) | 0.066 | 0.076 | 51 (39–63) | 40 (28–52) | 1.29 (0.81–2.03) | 0.281 | 0.275 |
Isotretionoin treatment | 26/9 | 45 (25–65) | 33 (2–64) | 1.79 (0.67–4.74) | 0.237 | 0.131 | 49 (29–69) | 44 (11–77) | 1.34 (0.47–3.81) | 0.583 | 0.583 |
Treated as randomised | |||||||||||
All | 75/70 | 46 (34–58) | 25 (15–35) | 2.07 (1.36–3.16) | 0.001 | 0.001 | 49 (37–61) | 31 (19–43) | 1.80 (1.16–2.79) | 0.008 | 0.005 |
CR/VGPR | |||||||||||
After induction chemotherapy | 54/50 | 49 (35–63) | 27 (15–39) | 2.35 (1.40–3.93) | 0.001 | 0.001 | 54 (50–58) | 33 (19–47) | 2.07 (1.21–3.53) | 0.007 | 0.004 |
PR/MR/SD after induction chemotherapy | 21/20 | 38 (16–60) | 21 (3–39) | 1.50 (0.71–3.16) | 0.286 | 0.187 | 38 (16–60) | 28 (6–50) | 1.27 (0.59–2.75) | 0.544 | 0.544 |
Raised LDH at diagnosis | 66/65 | 44 (32–56) | 27 (15–39) | 1.85 (1.19–2.88) | 0.006 | 0.006 | 47 (35–59) | 31 (19–43) | 1.72 (1.09–2.71) | 0.018 | 0.013 |
Normal LDH at diagnosis | 7/4 | 69 (34–104) | N.A. | N.A. | N.A. | N.A. | 69 (34–104) | 25 (N.A.) | 4.62 (0.74–28.69) | 0.073 | 0.073 |
MYCN amplification | 35/28 | 37 (21–53) | 20 (4–36) | 2.06 (1.13–3.77) | 0.016 | 0.016 | 40 (24–56) | 20 (4–36) | 2.09 (1.13–3.86) | 0.016 | 0.016 |
No MYCN amplification | 40/41 | 54 (38–70) | 27 (13–41) | 2.43 (1.33–4.45) | 0.003 | 0.003 | 57 (41–73) | 38 (22–54) | 1.86 (0.98–3.50) | 0.052 | 0.035 |
Stage 4 and age >1 year | 67/58 | 44 (32–56) | 24 (12–36) | 1.97 (1.26–3.09) | 0.003 | 0.002 | 46 (34–58) | 32 (20–44) | 1.64 (1.03–2.61) | 0.035 | 0.025 |
Stage 1, 2, 3, or 4S or stage 4 age <1 year | 8/12 | 60 (25–95) | 30 (3–57) | 3.14 (0.82–12.04) | 0.079 | 0.079 | 73 (42–104) | 30 (3–57) | 4.15 (0.87–19.72) | 0.053 | 0.053 |
ch14.18 treatment | 54/52 | 49 (35–63) | 30 (18–42) | 1.87 (1.12–3.11) | 0.015 | 0.020 | 53 (39–67) | 39 (25–53) | 1.58 (0.92–2.70) | 0.094 | 0.068 |
Isotretinoin treatment | 17/4 | 48 (32–64) | 50 (1–99) | 1.20 (0.25–5.66) | 0.820 | 0.551 | 48 (23–73) | 50 (1–99) | 1.00 (0.21–4.69) | 0.994 | 0.994 |
